• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

Card Range To Study

through

image

Play button

image

Play button

image

Progress

1/60

Click to flip

Use LEFT and RIGHT arrow keys to navigate between flashcards;

Use UP and DOWN arrow keys to flip the card;

H to show hint;

A reads text to speech;

60 Cards in this Set

  • Front
  • Back
A malignant ds of blood-forming organs; 8% of cancers
LEUKEMIA
Most common leukemia in children and young adults
LYMPHATIC LEUKEMIA 80%
Risk factors to leukemia
BENZENE, ALKYLATING AGENTS, DOWN SYNDROME, HTLV-1
Pathophysiology of leukemia
uncontrolled leukocyte production, undifferentiated leuks (blasts) with infiltration of blood forming organs
Classification of leukemias
morphological characteristics thru staining of blast cells
50% of marrow cells are immature
ACUTE LEUKEMIA
Two forms of acute leukemia
LYMPHOCYTIC AND NONLYMPHOCYTIC
A reduction in all cellular components of the blood
PANCYTOPENIA
Most common in children (11 yrs)
all
Common in adults (67 yrs)
aml
Involves rapid accumulation of hematopoietic stem cells
AML
HX involves military and powerplants, radiation, meds
AML
s/s sudden hi-fever, bruising, petecheae, bleeding, blurred vision, DIC
AML
defect in hematopoietic stem cells
AML
drugs for AML
IDARUBICIN, NOVANTRONE, CYTOSAR
complication of radiation in AML patients
TUMOR LYSIS SYNDROME
treatment of AML
drugs, BMT, PRBC, RADIATION, CHEMO
Hallmark sign of AML
neutropenia
Characterized by uncontrollable spread of small B lymphocytes
CLL
Most common in US leukemia
CLL
Least malignant form of leukemia; takes as long as 15 yrs
CLL
Characterized by abnormal overgrowth of myeloblasts
CML
Mutating myeloid stem cells
CML
Has two phases: insidious chronic phase and acute (blast) phase
CML
Drugs to treat CML
IMATINIB, INTERFERON
Drugs to treat CLL
fludarabine, CHLORAMBUCIL, RITUXIMAB
Enlarged lymph nodes, anemia, ITP, hemolytic anemia, ANERGY, herpes
CLL
Drugs to treat ALL
IMATINIB, CAMPATH
Presence of philly or chromosome 22
CML
Results from abnormal production of granulocytic cells
CML
Presence of REED-Sternberg cells
HODGKIN’S LYMPHOMA
Suspects EPSTEIN-Barr virus, MONO, JEWS
HODGKIN’s lymphoma
Painless progressive enlargement of LN, with increased lymphocytes, histiocytes and eosinophils and REED Sternberg giant cells
HODGKIN’S
Non-productive cough with mediastinal mass in 50% of patients
HODGKINS
Presence of B-symptoms
HODGKINS
Treatment for hodgkin’s
radiation/chemo, combo
Presence of neoplastic growth of lymphoid tissue
NON-HODGKIN’S
Random proliferation of lymphocytes originating from lymphoid cells
non-HODGKIN’S
7X MORE COMMON than hodgkin’s; 60X ON aids pts
non-HODGKINS
6th common cause of cancer/deaths
non-HODGKINS
What are B symptoms
fever, night sweats, weight loss > 10%
Abnormal mass of tissue that harms host organism
NEOPLASM
A stem cell disorder within the bone marrow
A stem cell disorder within the bone marrow
Caused by increased platelet production
SECONDARY THROMBOCYTOPENIA
Can result from decreased production, increased destruction/consumption of platelets
THROMBOCYTOPENIA
Phagocytic engulfement of platelets due to
ITP
Caused by genetic defect that results in deficient or defective factor VIII
Hemophilia A-eight
Caused by genetic defect that results in deficient or defective factor IX
Hemophilia B-nine
A defect in a factor that necessitates adhesion of factor VIII
Von Willebrand’s Ds
Medical goals for hemophilia
STOP BLEEDING, RAISE AHF by infusion of VIII and IX (Eight/nine)
Therapies for blood disorders
SPLENECTOMY, APHERESIS, PHLEBOTOMY, TRANSFUSIONS
Transfusion complications
fever, hemolysis, allergic rxn, circulatory overload, infection, lung injury, delayed hemolytic rxn, iron toxicity, long-term complications
Life threatening disorder in which bleeding and coagulation occur simultaneously
DIC
Disorder with presence of microclots in capillaries, micro-infarcts, FDPs
DIC
Occurs as a response to shock, trauma, cirrhosis, conditions releasing factor III such as fat emboli, snake bits, abruption placenta, IUFD
DIC
Can occur with women who developed PIH
DIC
Lab values for DIC
PLATELETS <100,000 , FIBRINOGEN <150, PTT >15 SECS, POSITIVE D-DIMERS
How to correct DIC
PRBCs, FFP, Cryoprecipitate, Platelets, Heparin, Bleeding control
When to use heparin (low dose 300-500) in DIC
acute renal failure and/or skin ischemia
DIC is marked by :
CLOTTING AND HEMMORHAGE (BLEEDING)